17 results on '"Giandomenico Schiena"'
Search Results
2. Economic impact of reducing treatment gaps in depression
- Author
-
Paul McCrone, Allan H. Young, Roland Zahn, Jonas Eberhard, Danuta Wasserman, Paolo Brambilla, Judit Balazs, Jose Caldas-de-Almeida, Andrea Ulrichsen, Vladmir Carli, Ana Antunes, Giandomenico Schiena, Vinciane Quoidbach, Patrice Boyer, and Rebecca Strawbridge
- Subjects
cost ,depression ,economics ,treatment ,gaps ,Psychiatry ,RC435-571 - Abstract
Abstract Background Major depressive disorder (MDD) is highly prevalent across Europe. While evidence-based treatments exist, many people with MDD have their condition undetected and/or untreated. This study aimed to assess the cost-effectiveness of reducing treatment gaps using a modeling approach. Methods A decision-tree model covering a 27-month time horizon was used. This followed a care pathway where MDD could be detected or not, and where different forms of treatment could be provided. Expected costs pertaining to Germany, Hungary, Italy, Portugal, Sweden, and the UK were calculated and quality-adjusted life years (QALYs) were estimated. The incremental costs per QALY of reducing detection and treatment gaps were estimated. Results The expected costs with a detection gap of 69% and treatment gap of 50% were €1236 in Germany, €476 in Hungary, €1413 in Italy, €938 in Portugal, €2093 in Sweden, and €1496 in the UK. The incremental costs per QALY of reducing the detection gap to 50% ranged from €2429 in Hungary to €10,686 in Sweden. The figures for reducing the treatment gap to 25% ranged from €3146 in Hungary to €13,843 in Sweden. Conclusions Reducing detection and treatment gaps, and maintaining current patterns of care, is likely to increase healthcare costs in the short term. However, outcomes are improved, and reducing these gaps to 50 and 25%, respectively, appears to be a cost-effective use of resources.
- Published
- 2023
- Full Text
- View/download PDF
3. Neuroimaging Correlates of Treatment Response to Transcranial Magnetic Stimulation in Bipolar Depression: A Systematic Review
- Author
-
Ahmad Shamabadi, Hanie Karimi, Giulia Cattarinussi, Hossein Sanjari Moghaddam, Shahin Akhondzadeh, Fabio Sambataro, Giandomenico Schiena, and Giuseppe Delvecchio
- Subjects
bipolar depression ,brain imaging ,functional neuroimaging ,systematic review ,transcranial magnetic stimulations ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Transcranial magnetic stimulation (TMS) has become a promising strategy for bipolar disorder (BD). This study reviews neuroimaging findings, indicating functional, structural, and metabolic brain changes associated with TMS in BD. Web of Science, Embase, Medline, and Google Scholar were searched without any restrictions for studies investigating neuroimaging biomarkers, through structural magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), functional MRI (fMRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), and single photon emission computed tomography (SPECT), in association with response to TMS in patients with BD. Eleven studies were included (fMRI = 4, MRI = 1, PET = 3, SPECT = 2, and MRS = 1). Important fMRI predictors of response to repetitive TMS (rTMS) included higher connectivity of emotion regulation and executive control regions. Prominent MRI predictors included lower ventromedial prefrontal cortex connectivity and lower superior frontal and caudal middle frontal volumes. SPECT studies found hypoconnectivity of the uncus/parahippocampal cortex and right thalamus in non-responders. The post-rTMS changes using fMRI mostly showed increased connectivity among the areas neighboring the coil. Increased blood perfusion was reported post-rTMS in PET and SPECT studies. Treatment response comparison between unipolar depression and BD revealed almost equal responses. Neuroimaging evidence suggests various correlates of response to rTMS in BD, which needs to be further replicated in future studies.
- Published
- 2023
- Full Text
- View/download PDF
4. Use of 30-Hz Accelerated iTBS in Drug-Resistant Unipolar and Bipolar Depression in a Public Healthcare Setting: A Case Series
- Author
-
Filippo Cantù, Giandomenico Schiena, Domenico Sciortino, Lorena Di Consoli, Giuseppe Delvecchio, Eleonora Maggioni, and Paolo Brambilla
- Subjects
iTBS ,accelerated ,TMS ,TRD ,depression ,Bipolar Disorder ,Psychiatry ,RC435-571 - Abstract
Background: Depressive episodes, especially when resistant to pharmacotherapy, are a hard challenge to face for clinicians and a leading cause of disability worldwide. Neuromodulation has emerged as a potential therapeutic option for treatment-resistant depression (TRD), in particular transcranial magnetic stimulation (TMS). In this article, we present a case series of six patients who received TMS with an accelerated intermittent theta-burst stimulation (iTBS) protocol in a public healthcare setting.Methods: We enrolled a total number of six participants, affected by a treatment-resistant depressive episode, in either Major Depressive Disorder (MDD) or Bipolar Disorder (BD). Patients underwent an accelerated iTBS protocol, targeted to the left dorsolateral prefrontal cortex (DLPFC), 3-week-long, with a total of 6 days of overall stimulation. On each stimulation day, the participants received 3 iTBS sessions, with a 15-min pause between them. Patients were assessed by the Hamilton Rating Scale for Depression (HAM-D), the Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Rating Scale for Anxiety (HAM-A), and the Mania Rating Scale (MRS). At baseline (T0), at the end of the second week (T1), and at the end of the cycle of stimulation (T2).Results: The rANOVA (repeated Analysis of Variance) statistics showed no significant effect of time on the rating scale scores, with a slight decrease in MADRS scores and a very slight increase in HAM-A and HAM-D scores. No manic symptoms emerged during the entire protocol.Conclusions: Although accelerated iTBS might be considered a less time-consuming strategy for TMS administration, useful in a public healthcare setting, our results in a real-word six-patient population with TRD did not show a significant effect. Further studies on wider samples are needed to fully elucidate the potential of accelerated iTBS protocols in treatment-resistant depression.
- Published
- 2022
- Full Text
- View/download PDF
5. Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study
- Author
-
Rebecca Strawbridge, Paul McCrone, Andrea Ulrichsen, Roland Zahn, Jonas Eberhard, Danuta Wasserman, Paolo Brambilla, Giandomenico Schiena, Ulrich Hegerl, Judit Balazs, Jose Caldas de Almeida, Ana Antunes, Spyridon Baltzis, Vladmir Carli, Vinciane Quoidbach, Patrice Boyer, and Allan H. Young
- Subjects
Care pathways ,diagnosis ,major depressive disorder ,treatment ,Psychiatry ,RC435-571 - Abstract
Abstract Background Despite well-established guidelines for managing major depressive disorder, its extensive disability burden persists. This Value of Treatment mission from the European Brain Council aimed to elucidate the nature and extent of “gaps” between best-practice and current-practice care, specifically to: 1. Identify current treatment gaps along the care pathway and determine the extent of these gaps in comparison with the stepped-care model and 2. Recommend policies intending to better meet patient needs (i.e., minimize treatment gaps). Methods After agreement upon a set of relevant treatment gaps, data pertaining to each gap were gathered and synthesized from several sources across six European countries. Subsequently, a modified Delphi approach was undertaken to attain consensus among an expert panel on proposed recommendations for minimizing treatment gaps. Results Four recommendations were made to increase the depression diagnosis rate (from ~50% episodes), aiming to both increase the number of patients seeking help, and the likelihood of a practitioner to correctly detect depression. These should reduce time to treatment (from ~1 to ~8 years after illness onset) and increase rates of treatment; nine further recommendations aimed to increase rates of treatment (from ~25 to ~50% of patients currently treated), mainly focused on targeting the best treatment to each patient. To improve follow-up after treatment initiation (from ~30 to ~65% followed up within 3 months), seven recommendations focused on increasing continuity of care. For those not responding, 10 recommendations focused on ensuring access to more specialist care (currently at rates of ~5–25% of patients). Conclusions The treatment gaps in depression care are substantial and concerning, from the proportion of people not entering care pathways to those stagnating in primary care with impairing and persistent illness. A wide range of recommendations can be made to enhance care throughout the pathway.
- Published
- 2022
- Full Text
- View/download PDF
6. Case Report: Repeated Transcranial Magnetic Stimulation Improves Comorbid Binge Eating Disorder in Two Female Patients With Treatment-Resistant Bipolar Depression
- Author
-
Domenico Sciortino, Giandomenico Schiena, Filippo Cantù, Eleonora Maggioni, and Paolo Brambilla
- Subjects
case report ,binge eating disorder ,intermittent theta burst stimulation ,bipolar disorder ,transcranial magnetic stimulation (TMS) ,Psychiatry ,RC435-571 - Abstract
Introduction: Binge eating disorder (BED) is the most common eating disorder, affecting a large population worldwide. It is characterized by recurrent episodes of binge eating, with no compensatory behaviors. BED is often associated with psychiatric comorbidities, and still represents a challenge in terms of treatment strategies. In the last years, neuromodulation has represented a promising approach in the treatment of BED. We report the cases of two women, affected by Bipolar Disorder Type II (BD-II) and comorbid BED, whose BED symptoms improved after a course of accelerated intermittent Theta Burst Stimulation (iTBS).Methods: We carried out a clinical study, involving neurostimulation on six patients with a treatment-resistant depressive episode. The trial consisted of a 3-week accelerated iTBS treatment, delivered to the left dorsolateral pre-frontal cortex. Clinical evaluation scales (Hamilton Rating Scale for Depression, Montgomery-Åsberg Depression Rating Scale, and Young Mania Rating Scale) were administered at baseline, after 2 weeks, and at the end of the stimulation cycle. Pharmacotherapy was maintained unchanged during iTBS treatment. Patients gave their informed consent both for the protocol and for the publication.Results: The treatment was well-tolerated. Depressive symptoms only slightly improved; however, patients' binge episodes remitted completely, which was a serendipitous finding. BED symptomatology complete remission lasted up to 12 weeks follow-up.Discussion: This is the first study regarding iTBS use in BED in comorbidity with BD-II. Further research is still needed to assess the efficacy of this technique in BED treatment.
- Published
- 2021
- Full Text
- View/download PDF
7. Exploring Brain Activity During Awe-Inducing Virtual Reality Experiences: a Multi-Metric EEG Frequency Analysis.
- Author
-
Flavia Carbone, Elena Bondi, Yara Massalha, Andrea Anastasi, Adele Ferro, Marta Pizzolante, Giandomenico Schiena, Anna Maria Maddalena Bianchi, Andrea Gaggioli, Maddalena Mazzocut-Mis, Alice Chirico, Paolo Brambilla, and Eleonora Maggioni
- Published
- 2024
- Full Text
- View/download PDF
8. Data-driven Discovery of the Central Autonomic Network: Dynamic Integration of HRV and Multivariate fMRI Connectivity.
- Author
-
Federica Goffi, Pierluigi Reali, Adele Ferro, Giandomenico Schiena, Fabio Maria Triulzi, Anna M. Bianchi, Paolo Brambilla, and Eleonora Maggioni
- Published
- 2024
- Full Text
- View/download PDF
9. Combining Metacognitive Therapy and tDCS: preliminary results in patients with Major Depressive Disorder
- Author
-
Fecteau, S, Bikson, M, Chandler, J, Giordano, J, Vergallito, A, Schiena, G, Maggioni, E, Sciortino, D, Casiraghi, L, Vedani, A, Melloni, M, Caselli, G, Maria Ruggiero, G, Sassaroli, S, Brambilla, P, ROMERO LAURO, L, Alessandra Vergallito, Giandomenico Schiena, Eleonora Maggioni, Domenico Sciortino, Letizia Casiraghi, Anna Vedani, Maria Costanza Melloni, Gabriele Caselli, Giovanni Maria Ruggiero, Sandra Sassaroli, Paolo Brambilla, Leonor Josefina Romero Lauro, Fecteau, S, Bikson, M, Chandler, J, Giordano, J, Vergallito, A, Schiena, G, Maggioni, E, Sciortino, D, Casiraghi, L, Vedani, A, Melloni, M, Caselli, G, Maria Ruggiero, G, Sassaroli, S, Brambilla, P, ROMERO LAURO, L, Alessandra Vergallito, Giandomenico Schiena, Eleonora Maggioni, Domenico Sciortino, Letizia Casiraghi, Anna Vedani, Maria Costanza Melloni, Gabriele Caselli, Giovanni Maria Ruggiero, Sandra Sassaroli, Paolo Brambilla, and Leonor Josefina Romero Lauro
- Abstract
Background and aim: Transcranial direct current stimulation (tDCS) and metacognitive therapy (MCT) can reduce depressive symptoms as monotherapies or associated with pharmacological treatment. Here, we investigated the effectiveness of combining these treatments in a group of patients with major depressive disorder (MDD). Methods: So far, fourteen participants (10 females, Mage 43 ± 12) out of N= 54 estimated sample size were recruited at the Department of Neuroscience and Mental Health – Fondazione IRRCS Ca’ Granda Ospedale Maggiore Policlinico of Milano. All participants were under pharmacological treatment. They were randomly assigned to three groups receiving (i) real tDCS + sham MCT (n= 7); (ii) sham tDCS + MCT (n = 6) (iii) real tDCS + MCT (n= 1). The treatment lasted eight weeks, in which participants had one weekly MCT (groups ii and iii) or clinical interview session (group i) following the tDCS. TDCS was combined with attentional training (20 minutes, 1.5 mA, anode over the left dorsolateral prefrontal cortex) and took place three times a week for the first three weeks and then once a week. Clinical standardized questionnaires measuring depressive symptoms, anxiety, worry, rumination, and meta-beliefs were administered before and after the treatment, two weeks, three, six, and twelve months after treatment’s end. Results: Due to sampling distribution, mixed effects models were run, including time and only two groups as fixed factors (i and ii) and participants’ random intercept. Outcome measures revealed an effect of time, showing symptoms reduction after the treatment. Crucially, our results suggested a more robust reduction of worry and negative beliefs in the group receiving MCT compared to the one receiving only tDCS. Conclusions: despite preliminary, our results suggest that MCT can effectively reduce core symptoms contributing to the development and maintenance of MDD. Completing data collection will allow disentangling whether tDCS can boost this ef
- Published
- 2023
10. Insula volumes in first-episode and chronic psychosis: A longitudinal MRI study
- Author
-
Alessandro Pigoni, Giuseppe Delvecchio, Nicola Dusi, Giandomenico Schiena, Angela Andreella, Livio Finos, Filippo Cecchetto, Cinzia Perlini, Maria Gloria Rossetti, Adele Ferro, Marcella Bellani, Antonio Lasalvia, Mirella Ruggeri, and Paolo Brambilla
- Subjects
Cerebral Cortex ,First episode psychosis ,Bipolar disorder ,Insula ,Magnetic resonance imaging ,Psychosis ,Schizophrenia ,Settore M-PSI/03 - Psicometria ,Psychiatry and Mental health ,Psychotic Disorders ,Humans ,Gray Matter ,Biological Psychiatry - Abstract
Alterations in insular grey matter (GM) volume has been consistently reported for affective and non-affective psychoses both in chronic and first-episode patients, ultimately suggesting that the insula might represent a good region to study in order to assess the longitudinal course of psychotic disorders. Therefore, in this longitudinal Magnetic Resonance Imaging (MRI) study, we aimed at further investigating the key role of insular volumes in psychosis.68 First-Episode Psychosis (FEP) patients, 68 patients with Schizophrenia (SCZ), 47 Bipolar Disorder (BD) patients, and 94 Healthy Controls (HC) were enrolled and underwent a 1.5 T MRI evaluation. A subsample of 99 subjects (10 HC, 23 BD, 29 SCZ, 37 FEP) was rescanned after 2,53 ± 1,68 years. The insular cortex was manually traced and then divided into an anterior and posterior portion. Group and correlation analyses were then performed both at baseline and at follow-up.At baseline, greater anterior and lower posterior insular GM volumes were observed in chronic patients. At follow-up, we found that FEP patients had a significant GM volume increase from baseline to follow-up, especially in the posterior insula whereas chronic patients showed a relative stability. Finally, significant negative correlations between illness severity and pharmacological treatment and insular GM volumes were observed in the whole group of psychotic patients.The longitudinal assessment of both chronic and first-episode patients allowed us to detect a complex pattern of GM abnormalities in selective sub-portions of insular volumes, ultimately suggesting that this structure could represent a key biological marker of psychotic disorders.
- Published
- 2022
11. Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
- Author
-
Valentina Ciappolino, Paolo Brambilla, Alessandro Pigoni, Gian Mario Mandolini, Lucio Oldani, Claudia Cinnante, Viviana Barbieri, Matteo Lazzaretti, Giuseppe Delvecchio, Elisabetta Caletti, Fabio Triulzi, and Giandomenico Schiena
- Subjects
Adult ,Male ,Psychosis ,medicine.medical_specialty ,Marijuana Abuse ,General Chemical Engineering ,Neuroimaging ,Pilot Projects ,Audiology ,Grey matter ,General Biochemistry, Genetics and Molecular Biology ,Psychoses, Substance-Induced ,Brief Psychiatric Rating Scale ,medicine ,Humans ,Gray Matter ,biology ,General Immunology and Microbiology ,business.industry ,General Neuroscience ,Brain morphometry ,Brain ,biology.organism_classification ,medicine.disease ,Magnetic Resonance Imaging ,medicine.anatomical_structure ,Female ,Cannabis ,business ,Psychosocial ,Insula - Abstract
Cannabis is the illicit drug most commonly used worldwide, and its consumption can both induce psychiatric symptoms in otherwise healthy subjects and unmask a florid psychotic picture in patients with a prior psychotic risk. Previous studies suggest that chronic and long-term cannabis exposure may exert significant negative effects in brain areas enriched with cannabinoid receptors. However, whether brain alterations determined by cannabis dependency will lead to a clinically significant phenotype or to a psychotic outbreak at some point of an abuser's life remains unclear. The aim of this study was to investigate morphological brain differences between chronic cannabis users with cannabis-induced psychosis (CIP) and non-psychotic cannabis users (NPCU) without any psychiatric conditions and correlate brain deficits with selective socio-demographic, clinical and psychosocial variables. 3T magnetic resonance imaging (MRI) scans of 10 CIP patients and 12 NPCU were acquired. The type of drug, the frequency, and the duration, as well socio-demographic, clinical and psychosocial parameters of dependency were measured. CIP patients had extensive grey matter (GM) decreases in right superior frontal gyrus, right precentral, right superior temporal gyrus, insula bilaterally, right precuneus, right medial occipital gyrus, right fusiform gyrus, and left hippocampus in comparison to chronic cannabis users without psychosis. Finally, in CIP patients, the results showed a negative correlation between a domain of the Brief Psychiatric Rating Scale (BPRS), BPRS-Activity, and selective GM volumes. Overall, the results suggest that cannabis-induced psychosis is characterized by selective brain reductions that are not present in NPCU. Therefore, neuroimaging studies may provide a potential ground for identifying putative biomarkers associated with the risk of developing psychosis in cannabis users.
- Published
- 2020
12. Transcranial direct current stimulation modulates implicit attitudes towards food in eating disorders
- Author
-
Sara Bertelli, Leonor J. Romero Lauro, Stefano Bonora, Armando D'Agostino, Costanza Papagno, Alessia Gallucci, Elena Tugnoli, Giandomenico Schiena, A. Benetti, Orsola Gambini, Giulia Mattavelli, Sandra Sassaroli, Giovanni Maria Ruggiero, Teresa Sassetti, Mattavelli, G, Gallucci, A, Schiena, G, D'Agostino, A, Sassetti, T, Bonora, S, Bertelli, S, Benetti, A, Tugnoli, E, Ruggiero, G, Sassaroli, S, Romero Lauro, L, Gambini, O, and Papagno, C
- Subjects
Adult ,Male ,non-invasive brain stimulation ,050103 clinical psychology ,medicine.medical_specialty ,body image ,medicine.medical_treatment ,Overweight ,Audiology ,Transcranial Direct Current Stimulation ,Affect (psychology) ,tDCS ,Feeding and Eating Disorders ,Extrastriate body area ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Feeding and Eating Disorder ,0501 psychology and cognitive sciences ,Transcranial direct-current stimulation ,business.industry ,digestive, oral, and skin physiology ,05 social sciences ,medicine.disease ,Neuromodulation (medicine) ,030227 psychiatry ,Psychiatry and Mental health ,Eating disorders ,implicit attitude ,Attitude ,eating disorder ,Female ,food preference ,Underweight ,medicine.symptom ,Implicit attitude ,business ,Human - Abstract
Objective Neuromodulation of regions involved in food processing is increasingly used in studies on eating behaviors, but results are controversial. We assessed the effects of anodal transcranial direct current stimulation (a-tDCS) on food and body implicit preferences in patients with eating disorders (EDs). Method Thirty-six ED patients and 36 healthy females completed three sessions with a-tDCS applied to the medial-prefrontal cortex (mPFC), the right extrastriate body area (rEBA) or in sham mode. Each participant then completed three Implicit Association Tests (IATs) on tasty/tasteless food, underweight/overweight body images, flowers versus insects as control. Differences in latency between incongruent and congruent blocks were calculated (D score). Results The tDCS by group interaction was significant for the IAT-food D score, with patients showing weaker preference for tasty food than controls in sham, but not a-tDCS sessions. In particular, rEBA stimulation significantly increased patients' D score compared to sham. Moreover, a-tDCS over mPFC and rEBA selectively increased patients' reaction times in the incongruent blocks of the IAT-food. Discussion A-tDCS on frontal and occipito-temporal cortices modulated food preferences in ED patients. The effect was specific for food images and selective in patients, but not in healthy participants. These findings suggest that neuromodulation of these regions could affect implicit food attitudes.
- Published
- 2019
- Full Text
- View/download PDF
13. Role of rTMS in the treatment of cognitive impairments in Bipolar Disorder and Schizophrenia: a review of Randomized Controlled Trials
- Author
-
Domenico Sciortino, Giandomenico Schiena, Alessandro Pigoni, Giuseppe Delvecchio, Eleonora Maggioni, and Paolo Brambilla
- Subjects
medicine.medical_specialty ,Bipolar Disorder ,medicine.medical_treatment ,major psychoses ,MEDLINE ,behavioral disciplines and activities ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Physical medicine and rehabilitation ,Pharmacotherapy ,Randomized controlled trial ,law ,rTMS ,mental disorders ,medicine ,Humans ,Cognitive Dysfunction ,Bipolar disorder ,Depression (differential diagnoses) ,Randomized Controlled Trials as Topic ,business.industry ,Cognition ,medicine.disease ,Transcranial Magnetic Stimulation ,030227 psychiatry ,Transcranial magnetic stimulation ,Psychiatry and Mental health ,Clinical Psychology ,Treatment Outcome ,nervous system ,Schizophrenia ,business ,030217 neurology & neurosurgery - Abstract
Background Schizophrenia (SCZ) and Bipolar Disorder (BD) are severe psychiatric illnesses often characterized by mild-to-severe cognitive deficits. Since available pharmacotherapy showed poor efficacy in treating these cognitive impairments, new strategies are needed. Repeated Transcranial Magnetic Stimulation (rTMS) represents a safe non-invasive technique that has been hypothesized to improve cognitive symptoms in these pathologies. Therefore, our brief review aims at summarizing the results of Randomized Controlled Trials (RCTs) using rTMS for improving cognitive symptoms in SCZ and BD. Methods We performed a bibliographic research on PubMed, Google Scholar and Medline of RCTs conducted in patients with BD and SCZ, which evaluated cognitive outcomes after rTMS treatment. Results The inclusion criteria were met by fifteen RCTs, twelve in SCZ and three in BD. Regarding patients with SCZ, the results showed that rTMS seemed to have poor effects on improving cognitive performances, with mixed results also observed for schizoaffective patients. In BD, overall the RCTs showed that rTMS in these patients seemed to improve cognitive domains in euthymic patients, while its effect during acute phases, especially depression, appeared limited. Limitations Studies employed different rTMS protocols and evaluated different cognitive domains. Conclusions Although the available evidence from RCTs evaluating the efficacy of rTMS on cognitive deficits in SCZ and BD are still mixed and heterogenous, overall they suggest that rTMS represents a potential clinical tool that could ameliorate cognitive symptoms, especially in specific patients’ subtypes. However, standardized protocols and further research are still necessary to evaluate the real efficacy of rTMS.
- Published
- 2020
14. Transcranial magnetic stimulation in major depressive disorder: Response modulation and state dependency
- Author
-
Paolo Brambilla, Sara Pozzoli, Eleonora Maggioni, and Giandomenico Schiena
- Subjects
MDD ,Antidepressant efficacy ,Depressive Disorder, Major ,business.industry ,medicine.medical_treatment ,Brain ,Stimulation ,Long-term potentiation ,medicine.disease ,Transcranial Magnetic Stimulation ,Antidepressive Agents ,Transcranial magnetic stimulation ,Psychiatry and Mental health ,Clinical Psychology ,Treatment Outcome ,TMS ,medicine ,Antidepressant ,Major depressive disorder ,State dependence ,Humans ,Neurostimulation ,business ,Neuroscience - Abstract
Background Transcranial Magnetic Stimulation (TMS) has emerged as a valid therapeutic option in the treatment of depression, especially in cases of inadequate response to antidepressant agents. Despite the recognized efficacy of this technique, its mechanisms of action are still debated and optimal protocols have not yet been established. Methods The present review focuses on TMS protocols that either engage the targeted brain circuits or synchronize the stimulation frequency to individual neuronal oscillations to increase the antidepressant efficacy. Results TMS efficacy was found to be enhanced by preliminary or concomitant modulation of the functional state of the targeted brain networks. Conversely, there is not enough evidence of higher efficacy of TMS protocols with individual selection of the stimulation frequency compared to standard ones. Limitations Most studies included small patient samples. Conclusions Our results suggest that a good option to enhance rTMS efficacy might be to follow synaptic potentiation and depression rules.
- Published
- 2019
15. Transcranial direct current stimulation (tdcs) modulates implicit attitudes towards food in eating disorders
- Author
-
T. Sassetti, A. Benetti, Orsola Gambini, Sara Bertelli, Armando D'Agostino, Sandra Sassaroli, Elena Tugnoli, Alessia Gallucci, Giulia Mattavelli, Stefano Bonora, Giandomenico Schiena, Giovanni Maria Ruggiero, Costanza Papagno, and L Romero Lauro
- Subjects
Eating disorders ,Transcranial direct-current stimulation ,General Neuroscience ,medicine.medical_treatment ,Biophysics ,medicine ,Neurology (clinical) ,Implicit attitude ,medicine.disease ,Psychology ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,Clinical psychology ,lcsh:RC321-571 - Published
- 2019
16. A chronobiological perspective on ketamine’s antidepressant efficacy
- Author
-
Edoardo G Ostinelli, Giandomenico Schiena, Orsola Gambini, and Armando D'Agostino
- Subjects
Pharmacology ,Antidepressant efficacy ,Psychotherapist ,business.industry ,Perspective (graphical) ,Pharmacology toxicology ,medicine ,Ketamine ,business ,medicine.drug - Published
- 2015
- Full Text
- View/download PDF
17. Changes of cortical excitability as markers of antidepressant response in bipolar depression: preliminary data obtained by combining transcranial magnetic stimulation (TMS) and electroencephalography (EEG)
- Author
-
Cristina Colombo, Francesco Benedetti, Paola Canali, Giandomenico Schiena, Enrico Smeraldi, Matteo Fecchio, Andrea Pigorini, Giovanna Sferrazza Papa, Adenauer G. Casali, Canali, P, Sferrazza Papa, G, Casali, A, Schiena, G, Fecchio, M, Pigorini, A, Smeraldi, E, Colombo, C, and Benedetti, F
- Subjects
Adult ,Male ,Light therapy ,Bipolar Disorder ,medicine.medical_treatment ,Prefrontal Cortex ,Electroencephalography ,Young Adult ,Neuroplasticity ,medicine ,Humans ,Bipolar disorder ,Major depressive episode ,Prefrontal cortex ,Evoked Potentials ,Biological Psychiatry ,Psychiatric Status Rating Scales ,medicine.diagnostic_test ,Middle Aged ,Phototherapy ,medicine.disease ,Transcranial Magnetic Stimulation ,Transcranial magnetic stimulation ,bipolar depression, cortical excitability, neuroplasticity, sleep deprivation, transcranial magnetic stimulation (TMS), electroencephalography (EEG) ,Psychiatry and Mental health ,Sleep deprivation ,Treatment Outcome ,Sleep Deprivation ,Female ,medicine.symptom ,Psychology ,Neuroscience - Abstract
Background It is still unclear which biological changes are needed to recover from a major depressive episode. Current perspectives focus on cortical synaptic neuroplasticity. Measures of cortical responses evoked by transcranial magnetic stimulation (TMS) change with sleep homeostasic pressure in humans and approximate measures of synaptic strength in animal models. Using repeated total sleep deprivation as a model of antidepressant treatment, we aimed to correlate recovery from depression with these measures of cortical excitability. Methods We recorded electroencephalographic responses to TMS in the prefrontal cortex of 21 depressed inpatients with bipolar disorder treated with repeated sleep deprivation combined with light therapy. We performed seven TMS/electroencephalography sessions during one week and calculated three measures of cortical excitability. Results Cortical excitability progressively increased during the antidepressant treatment and as a function of time awake. Higher values differentiated responders from non-responders at baseline and during and after treatment on all measures. Conclusions Changes in measures of cortical excitability parallel and predict antidepressant response to combined sleep deprivation and light therapy. Data suggest that promoting cortical plasticity in bipolar depression could be a major effect of successful antidepressant treatments, and that patients not responding could suffer a persistent impairment in their neuroplasticity mechanisms.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.